Literature DB >> 12115815

Ultrasound-compacted indomethacin/polyvinylpyrrolidone systems: effect of compaction process on particle morphology and dissolution behavior.

Adamo Fini1, Maria Angeles Holgado, Lorenzo Rodriguez, Cristina Cavallari.   

Abstract

Indomethacin (IMC)/polyvinylpyrrolidone systems were prepared under different technological conditions, using co-evaporation, kneading, traditional, and ultrasound (US) compaction. The materials thus obtained were milled and sieved and the powders were analyzed by using scanning electron microscopy to evaluate the morphology of the final particles and the fractal dimension of the particle contour. In the case of US-treated particles, scanning electron micrographs suggest that IMC could have partially covered the excipient granule surface, which appears lustrous and smooth, whereas after co-evaporation, the particles display a stratified structure. The external color of the granules, the hot stage microscopy examination, and the absence of the melting peak of the drug in thermograms supports the idea that IMC converts into an amorphous form under US discharge. Each technological treatment performed on the binary mixtures increases the dissolution rate of the drug, with respect to the pure drug and the physical mixture, but to a lesser extent than US compaction. US compaction and co-evaporation produce comparable results in improving the release of the drug. Polyvinylpyrrolidone offers better results than beta-cyclodextrin in promoting the dissolution of IMC, when both systems are compacted under US. Copyright 2002 Wiley-Liss Inc. and the American Pharmaceutical Association

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115815     DOI: 10.1002/jps.10185

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  1 in total

1.  Enhanced release of indomethacin from Pvp/stearic acid microcapsules prepared coupling Co-freeze-drying and ultrasound assisted spray-congealing process.

Authors:  Cristina Cavallari; Barbara Luppi; Anna Maria Di Pietra; Lorenzo Rodriguez; Adamo Fini
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.